Fundamental Analysis of Pliant Therapeutics Inc - Growth / Value Index


PLRX - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 831.37 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -2500.78 -5774.09 -110885.81 %
Price to Book 897.81 1893.34 92368.63 % 2.10
Price to Sales 88543.69 252931 381711 %
Enterprise Value to EBITDA Multiple -4.73 -5891.17 -110857.79 %


PLRX - Profitability Highlights

Profitability Analysis

   Excellent QoQ /QoQ FY EPS growth
   Tsr Profitability Index - Very Poor Score of 5.00
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   EPS decline for last four quarters
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -35.90 -32.79 16.68 % -10.74
Return On Asset -32.79 -30.32 13.80 % -9.00
Net Profit Margin -3540.65 -4380.45 -244.02 % 0
Operating Profit Margin -3821.58 -4922.65 -274.81 % 0
EBITDA Margin -3612.91 -4293.15 -255.90 % 0


Highlights
Market Cap921174 K
Enterprise Value869312 K
Price/Book TTM897.81
Outstanding Share60325.80 K
Float/ Outstanding Share76.81%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score3.00
Altman Z Score13.09
Sloan Ratio-0.064
Peter Lynch Fair Value0


PLRX - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 244.02%
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Poor Score of 21.38
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 63.40 % from last year
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 5088.00 K 63.40 % 100.00 %
Gross Profit 320000 83.69 % 131.47 %
EBITDA -183825.00 K 30.27 % 43.86 %
Net Profit -180148.00 K 25.92 % 7.05 %
EPS -0.0061 99.91 % NA


PLRX - Stability Highlights

Stability Analysis

   Altman Z Score of 12.03 suggests good Stability
   Cash ratio of 17.33
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -121.95
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0240 -39.25 % 0.070
Cash Ratio 17.33 25.11 %
Quick Ratio 0 0 % 16.12
Shareholders Equity 92.47 3.47 %
Debt to EBITDA -0.075 29.52 %


Historical Valuation Ratios of Pliant Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Pliant Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Pliant Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Pliant Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)